Repotrectinib, marketed under the brand name Augtyro, was FDA approved on November 15, 2023.

DefenCath was approved by the U.S. Food and Drug Administration on November 15, 2023.

Adzynma was approved by the U.S. Food and Drug Administration on November 9, 2023.

Ixchiq, the world's first chikungunya vaccine, was approved by the U.S. Food and Drug Administration on November 9, 2023.

Vamorolone, marketed under the brand name Agamree, was approved by the FDA on October 26, 2023.

Cabtreo, a combination of clindamycin phosphate, adapalene, and benzoyl peroxide, was FDA-approved on October 20, 2023.

Sitagliptin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus in adults. This approval was first granted on October 18, 2006.

etrasimod (Velsipity) is FDA approved. The FDA granted its approval on October 12, 2023. This approval allows for the use of etrasimod in the treatment of adults with moderately to severely active ulcerative colitis.

Momelotinib, marketed under the brand name Ojjaara, was approved by the FDA on September 15, 2023.

Motixafortide, marketed under the brand name Aphexda, was approved by the FDA on September 8, 2023.

Pozelimab, marketed under the brand name Veopoz, is FDA approved.

Elranatamab, marketed under the brand name Elrexfio, is FDA approved. It received FDA approval for the treatment of adults with multiple myeloma.